Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 10/25/26 | Inhibrx (INBX) | INBRX-106 for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/25/26 | Akeso (9926) | Idafang for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/25/26 | Roche (RO) | divarasib for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/25/26 | AstraZeneca (AZN) | sonesitatug vedotin for Esophageal Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/25/26 | AstraZeneca (AZN) | sonesitatug vedotin for Gastric Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - sNDA/sBLA Filing |
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |